JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Mohammed S.A. | |
| dc.contributor.author | Elhabak M.A. | |
| dc.contributor.author | Eldardiri M. | |
| dc.contributor.other | National Organization of Drug Control and Research | |
| dc.contributor.other | Dokki | |
| dc.contributor.other | Egypt; Pharmaceutics Department | |
| dc.contributor.other | Faculty of Pharmacy | |
| dc.contributor.other | Alahrm | |
| dc.contributor.other | Canadian University | |
| dc.contributor.other | Giza | |
| dc.contributor.other | Egypt; Bioequivalence Center | |
| dc.contributor.other | Modern Science and Arts University | |
| dc.contributor.other | 6th October | |
| dc.contributor.other | Egypt | |
| dc.date.accessioned | 2020-01-09T20:40:44Z | |
| dc.date.available | 2020-01-09T20:40:44Z | |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 18785352 | |
| dc.identifier.other | https://doi.org/10.1016/j.arabjc.2019.02.004 | |
| dc.identifier.other | PubMed ID : | |
| dc.identifier.uri | https://t.ly/j6ve8 | |
| dc.description | Scopus | |
| dc.description.abstract | A simple, rapid and fully-validated liquid chromatographic method (RP - HPLC) with fluorescence detection was developed for the analysis of rhein (as the main metabolite of diacerein) in human plasma. The separation was performed using an ODS C 18 column with a mobile phase consisted of acetonitrile:methanol:phosphate buffer pH 6.8 and the flow rate was1.0 mL/min. The flourimetric detection was performed at 2 excitation wavelengths ? ex = 440 nm & 338 nm and one emission wavelength at ? em = 520 nm. The developed method was validated according to Food and Drug administration (FDA) guidelines for bioanalytical method validation. The pharmacokinetic parameters of the test and the reference were determined and the analysis of variance (ANOVA) between parameters of the two brands was calculated. The relative bioavailability was found to be 89%. This method was successfully applied for the routine bioequivalence analysis of diacerein in plasma. � 2019 | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=19400158709&tip=sid&clean=0 | |
| dc.language.iso | English | en_US |
| dc.publisher | Elsevier B.V. | en_US |
| dc.relation.ispartofseries | Arabian Journal of Chemistry | |
| dc.subject | Bioequivalence | en_US |
| dc.subject | Diacerein | en_US |
| dc.subject | HPLC flourimetry | en_US |
| dc.subject | Rhein | en_US |
| dc.subject | Biochemistry | en_US |
| dc.subject | Chromatographic analysis | en_US |
| dc.subject | Liquid chromatography | en_US |
| dc.subject | Metabolites | en_US |
| dc.subject | Pharmacokinetics | en_US |
| dc.subject | Bioequivalence | en_US |
| dc.subject | Chromatographic methods | en_US |
| dc.subject | Diacerein | en_US |
| dc.subject | Food and Drug Administration | en_US |
| dc.subject | HPLC flourimetry | en_US |
| dc.subject | Pharmacokinetic parameters | en_US |
| dc.subject | Relative bioavailability | en_US |
| dc.subject | Rhein | en_US |
| dc.subject | Analysis of variance (ANOVA) | en_US |
| dc.title | Pharmacokinetics and bioequivalence study of rhein as the main metabolite of diacerein | en_US |
| dc.type | Article | en_US |
| dcterms.isReferencedBy | Bolton, S., Bon, C., (2009), 80, pp. 384-443. , Experimental design in clinical trial. Pharmaceutical Statistics Practical and Clinical Applications fifth ed. Marcel Dekker Inc., New York; Chakrabarty, U.S., Mandal, U.D., Bhaumik, U., Chatterjee, B., Ghosh, A., Bose, A., Pal, T.K., (2008) Arzneimittelforschung, 58 (8), pp. 405-409; Chow, C.S., Liu, J.P., Design and Analysis of Bioavailability and Bioequivalence Studies (1992), Marcel Dekker New York; Debord, P., Louchahi, K., Tod, M., Cournot, A., Perret, G., Petitjean, O., (1994) Eur. J. Drug Metab. Pharmacokin., 19 (1), pp. 13-19; Grahnen, A., Design of bioavailability studies (1984) Pharm. Int., 5, pp. 100-103; Guidance for Industry, Bioanlytical Method Validation (2018), U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research, CDER Rockville, Maryland; Guidance for Industry, Statistical Approaches in Establishing Bioequivalence (2001), Rockville, Maryland: U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research, CDER; (1996), ICH harmonised tripartite guideline, good clinical practice, (E6)R1 US; Jiang, J.Y., Yang, M.W., Qian, W., Lin, H., Geng, Y., Zhou, Z.Q., Xiao, D.W., (2012) J. Pharmac. Biomed. Anal., 57 (5), pp. 19-25; Layek, B., Kumar, T.S., Trivedi, R.K., Mullangi, R., Srinivas, N.R., (2008) Biomed. Chromatogr., 22, pp. 616-624; Nicolas, P., Tod, M., Padoin, C., Petitjean, O., (1998) Clin. Pharmacokin., 35, pp. 347-359; Ojha, A., Rathod, R., Padh, H., (2009) J. Chromatogr. B, 877 (11-12), pp. 1145-1148; Spencer, C.M., Wilde, M.I., Diacerein (1997) Drugs, 53 (1), pp. 98-106; Tamura, T., Ohmori, K., (2001) Jpn. J. Pharmacol., 85, pp. 101-104; Tang, W., Huang, X., Yu, Q., Qin, F., Wan, M., Wang, Y., Liang, M., (2007) Biomed. Chromatogr., 21, pp. 1186-1190; Toegel, S., Huang, W., Piana, C., Unger, F.M., Wirth, M., Goldring, M.B., (2007) BMC Mol. Biol., 8. , -2199-8-13.1471-2199; (2018), Guidance for Industry: Bioanalytical Method Validation (last accessed on 02/11/2008); Verbruggen, G., (2006) Rheumatology (Oxford), 45 (2), pp. 129-138; Westlake, W.J., Bioavailability and bioequivalence of pharmaceutical formulations (1988) Biopharmaceutical Statistics for Drug Development, pp. 329-352. , K.E. Peace Marcel Dekker New York; Yaroshenkoa, I.S., Khaimenovb, A.Y., Grigoriev, A.V., Sidorova, A.A., (2014) J. Anal. Chem., 69 (8), pp. 793-799; Yi, L., Ping, G.J., Xua, X., Lixin, D., (2006) J. Chromat., 1, pp. 50-55 | |
| dcterms.source | Scopus | |
| dc.identifier.doi | https://doi.org/10.1016/j.arabjc.2019.02.004 | |
| dc.identifier.doi | PubMed ID : | |
| dc.Affiliation | October University for modern sciences and Arts (MSA) |
